Navigation Links
The Japanese Cancer Association and Debiopharm Group(TM) Present the JCA-Mauvernay Award to Dr Ogawa and Prof. Maeda for Their Outstanding Oncology Research
Date:9/24/2010

The Japanese Cancer Association and Debiopharm Group(TM) Present the JCA-Mauvernay Award to... -- LAUSANNE, Switzerland, September 24, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Medical Pharmaceuticals, Pharmaceuticals, Awards Click to view news release full screen  

The Japanese Cancer Association and Debiopharm Group(TM) Present the JCA-Mauvernay Award to Dr Ogawa and Prof. Maeda for Their Outstanding Oncology Research

 

LAUSANNE, Switzerland, September 24, 2010 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, today presented the 'The JCA-Mauvernay Award' to Doctor Seishi Ogawa from the University of Tokyo, for his research on cancer genome analysis and to Professor Shin Maeda from Yokohama City University of Medicine, for his research on liver carcinogenesis. The ceremony was held during the General Assembly of the 69th Annual Conference of the Japan Cancer Association (JCA) in Japan. Professor Tetsuo Noda, President of the JCA and Dr Rolland-Yves Mauvernay, Founder and President of Debiopharm Group(TM) presented both scientists with the Award for their outstanding and innovative research.

Seishi Ogawa is the Project Associate Professor of the Cancer Genomics Project at the University of Tokyo. His research work focuses on the "Identification of molecular targets in cancers through comprehensive cancer genome analysis". The aim of Dr Ogawa's studies is to identify the genetic changes that lead to malignant disorders. One way to achieve this is by the complete dissection of cancer genomes using genome-wide analysis, with tools such as single-nucleotide polymorphisms (SNP) genotype microarrays. Dr Ogawa and his colleagues developed a robust and efficient system to detect copy number alterations as well as allelic imbalances in cancer genomes. This work allowed the identification of a number of mutations associated with particular forms of neoplasms and their relevance is currently being analysed in a number of clinical studies.

Shin Maeda is Professor of the Department of Gastroenterology at the Yokohama City University Graduate School of Medicine. His research focuses on "Analysis of NF-kappaB/IKK signalling pathways in liver carcinogenesis". More specifically on the idea that the NF-kappaB/ IKK (inhibitor of nuclear factor kappa-B kinase) signalling pathways play an important role in the regulation of immune responses, inflammation and cancer, and are therefore attractive targets for the development of anti-cancer drugs. His research in mice shows that deletion of IKK-beta in hepatocytes enhances the formation of chemically-induced hepatocellular carcinomas (HCC), whereas a full deletion of IKK-beta in whole liver cells decreases HCC formation. These findings allowed Prof. Maeda to propose a model whereby chemical carcinogenesis is strongly dependent on inflammatory crosstalk.

"We congratulate Professor Maeda and Doctor Ogawa for excellent quality of their research," said Rolland-Yves Mauvernay, president and founder of Debiopharm Group(TM). "Their work provides insights, through different angles on the signalling pathways that are responsible for the oncogenic process in different malignancies. This understanding will ultimately lead to the development of new anti-cancer drugs."

About Debiopharm Group(TM)

Debiopharm Group(TM) (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III. Debiopharm is also prepared to consider earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Besides drug development, Debiopharm Group has recently embarked in the field of companion diagnostics with a view to progressing in the area of personalised medicine.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information on Debiopharm Group(TM), please visit: http://www.debiopharm.com.

Debiopharm S.A. Contact Maurice Wagner Director Corporate Affairs & Communication Tel.: +41(0)21-321-01-11 Fax: +41(0)21-321-01-69 mwagner@debiopharm.com Additional Media Contacts In London Maitland Brian Hudspith Tel: +44(0)20-7379-5151 bhudspith@maitland.co.uk In New York Russo Partners, LLC Martina Schwarzkopf, Ph.D. Account Executive Tel: +1-212-845-4292 Fax: +1-212-845-4260 martina.schwarzkopf@russopartnersllc.com
'/>"/>

SOURCE Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. COPAN Secures Japanese Patent for its Flocked Swab Innovation
2. Spirus Medical Announces Japanese Regulatory Approval to Market ENDO-EASE® Product Line
3. Will MHLW Changes in Reimbursement Drive Japanese Physicians to Increase Usage of Chronic Dialysis Catheters?
4. Reportlinker Adds Japanese Market for Small Joint Reconstructive Devices 2010
5. YesDTC Holdings and BioElectronics Receive Japanese Regulatory Review Date
6. BioElectronics and YesDTC Holdings Receive Japanese Regulatory Review Date
7. EUSA Pharma Grants Japanese Rights to Erwinase(R) Oncology Therapy to Ohara Pharmaceutical
8. CEM Announces Formation of Japanese Subsidiary
9. Leading Japanese University Powers Diagnostic Imaging Research With Isilon IQ
10. Boston Scientific Announces Japanese Approval for PROMUS(R) Everolimus-Eluting Coronary Stent System
11. Japanese Peripheral Vascular Stent Procedures to Experience 11% Growth Through 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. ... big data solutions, today announced that its MyDario product is expected to ... TV listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, ... ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound energy ... ... Jim Bertolina, PhD ... Tom Tefft ... executive Josh Stopek , PhD, who has led R&D and business development teams at ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, ... Dallas, Miami, and Raleigh regions, is organizing an extended charity drive to benefit ... deadly chromosome abnormality. , After struggling since birth with several health challenges, T.J. ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... certification process to promote standards of excellence for the field of eating disorders, ... March 22 – 25, 2018 in Orlando, Florida at the Omni Resort at ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
Breaking Medicine News(10 mins):